PharmaEssentia Corporation (6446.TW)
- Previous Close
515.00 - Open
506.00 - Bid 494.00 x --
- Ask 494.50 x --
- Day's Range
488.50 - 506.00 - 52 Week Range
308.00 - 796.00 - Volume
1,187,650 - Avg. Volume
2,450,892 - Market Cap (intraday)
159.883B - Beta (5Y Monthly) -0.03
- PE Ratio (TTM)
42.30 - EPS (TTM)
11.69 - Earnings Date Aug 11, 2025 - Aug 15, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
700.50
PharmaEssentia Corporation, a biopharmaceutical company engages in treatment for human diseases in Taiwan and internationally. Its products include Ropeginterferon alfa-2b that is used for the treatment of chronic myelogenous leukemia, T-Cell leukemia, early myelofibrosis, polycythemia vera, and essential thrombocythemia. The company also develops TCRT, anti PD-1, PEG-cytokine X,Y, and novel checkpoint abs for the treatment of solid tumors; P1101 + anti PD-1 for the treatment of hepatocellular carcinoma; and PEG-GCSF for the treatment of neutropenia. In addition, it focuses on the drug research and development programs in the areas of hematology, infectious disease, and oncology. PharmaEssentia Corporation was founded in 1990 and is headquartered in Taipei, Taiwan.
www.pharmaessentia.com--
Full Time Employees
December 31
Fiscal Year Ends
Sector
Recent News: 6446.TW
View MorePerformance Overview: 6446.TW
Trailing total returns as of 5/12/2025, which may include dividends or other distributions. Benchmark is TSEC CAPITALIZATION WEIGHTED ST (^TWII) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: 6446.TW
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 6446.TW
View MoreValuation Measures
Market Cap
166.51B
Enterprise Value
145.44B
Trailing P/E
44.13
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
15.18
Price/Book (mrq)
5.72
Enterprise Value/Revenue
12.83
Enterprise Value/EBITDA
32.19
Financial Highlights
Profitability and Income Statement
Profit Margin
34.38%
Return on Assets (ttm)
5.86%
Return on Equity (ttm)
14.56%
Revenue (ttm)
11.34B
Net Income Avi to Common (ttm)
3.9B
Diluted EPS (ttm)
11.69
Balance Sheet and Cash Flow
Total Cash (mrq)
22.06B
Total Debt/Equity (mrq)
3.35%
Levered Free Cash Flow (ttm)
1.25B